In a population-based
study* of 9429 patients
with MPNs, including
3001 with PV
In a population-based study* of 9429 patients
with MPNs, including 3001 with PV
in patients with PV
vs matched controls
in patients with PV vs matched controls HR, 4.2; CI, 3.5–5.0
In the CYTO-PV study† of 365 patients with PV
In the CYTO-PV study† of 365 patients with PV with elevated Hct between 45% and 50%
In the CYTO-PV study† of 365 patients with PV
of cardiovascular
death and major
thrombosis in patients
managed at a Hct target
level of 45 to 50% vs Hct
level managed to <45%2
†In the CYTO-PV study of 365 adult patients with PV treated with PBT, HU, or both, patients were randomized to 1 of 2 groups—either the low-Hct group (n = 182; with more intensive therapy to maintain a target Hct level <45%) or the high-Hct group (n = 183; with less intensive therapy to maintain a target Hct level of 45% to 50%). Baseline characteristics were balanced between the groups. Approximately 50% of patients had received an initial diagnosis of PV within 2 years prior to randomization. 67.1% of patients (n = 245) were at high risk because of age ≥65 years or previous thrombosis. The composite primary endpoint was the time until cardiovascular death or major thrombosis.2
In an additional analysis† from the CYTO-PV study
Elevated WBC counts >11 × 109/L increased the risk of thrombosis3
†In the CYTO-PV study of 365 adult patients with PV treated with PBT, HU, or both, patients were randomized to 1 of 2 groups—either the low-Hct group (n = 182; with more intensive therapy to maintain a target Hct level <45%) or the high-Hct group (n = 183; with less intensive therapy to maintain a target Hct level of 45% to 50%). Baseline characteristics were balanced between the groups. Approximately 50% of patients had received an initial diagnosis of PV within 2 years prior to randomization. 67.1% of patients (n = 245) were at high risk because of age ≥65 years or previous thrombosis. The composite primary endpoint was the time until cardiovascular death or major thrombosis.2
TEs are a major cause of mortality among patients with PV4
In the REVEAL
study,§ a prospective
observational study of
2510 patients with PV,
of the 175 patients with
known cause of death
§REVEAL was a prospective, observational study of 2510 adult patients with PV in the United States, sponsored by Incyte. Patients were enrolled over an approximate 2-year period (July 2014 to August 2016). This analysis included all enrolled patients and evaluated characteristics of deceased patients, survival by risk, and causes of death over the course of the study. A total of 244 patients died during the study, with 190 having elevated Hct values and WBC counts in the 6 months before death, and 175 having a known cause of death. Among the 244 patients who died during the study, 82% (n = 200) were categorized as high risk at diagnosis, primarily due to age ≥60 years only (65%; n = 159).4,5
In a survey|| of 147 employed patients with MPNs, including 55 with PV
|| The Living with MPNs patient survey was a cross-sectional online questionnaire of 904 MPN patients conducted April to November 2016. Symptom burden and functional status were compared in patients who reported taking medical disability leave (MDL) due to their MPN vs patients who reported no changes in employment status. Among the 592 patients who were employed full- or part-time at diagnosis, 147 (24.8%) reported taking ≥1 MDL (MF, 37.9%; PV, 22.2%; ET, 15.3%) vs 293 (49.4%) who reported no change in employment status as a result of their MPN. Of the patients who took MDL, 29.9% took ≥2 MDLs, and most patients (62.6%) did not return to work.6 This is a Incyte-sponsored survey.
*Population-based study based on Swedish Cancer Registry data for 1987-2009 in 9429 patients with MPNs. 9429 MPN patients (PV=3001, ET=3462, PMF=1488, and MPN-U=1478) and 35,820 matched controls were identified and included in the study. Hazard ratio for thrombosis at 3 months post-diagnosis was 4.2 for PV (95% CI, 3.5–5.0) vs
4.0 for all MPNs (95% CI, 3.6–4.4).1
for patients with advanced PV who are at risk of a thrombotic event8,9
A retrospective
cross-sectional analysis*
of US healthcare resource
utilization and costs
for adult patients with
PV and TEs demonstrated
A retrospective cross-sectional analysis*
of US healthcare resource utilization and costs
for adult patients with PV and TEs demonstrated
Patients with TEs
demand greater
healthcare
resources vs those
without TEs7
$45,040 mean total
annual costs for patients
with PV and TEs vs
$16,438 for those
without TEs (P < 0.001)
$45,040 mean total annual costs for patients with PV and TEs vs $16,438 for those without TEs (P < 0.001)
The same retrospective
analysis* demonstrated
that patients with PV and
TEs had higher rates of
inpatient healthcare
resource utilization
The same retrospective analysis* demonstrated that
patients with PV and TEs had higher rates of inpatient
healthcare resource utilization
50.9% (110/216)
for those with TEs
vs 18.4% (203/1106)
for those without
TEs (P < 0.001)
50.9% (110/216)
for those with TEs vs
18.4% (203/1106) for those
without TEs (P < 0.001)
*Retrospective cross-sectional database analysis including 1322 adult patients with a PV diagnosis who were newly treated with hydroxyurea and continuously enrolled in medical and pharmacy benefit plans for ≥12 months pre- and post-index. Healthcare resource utilization and costs were analyzed in a subgroup analysis comparing patients who had TEs in the 12-month follow-up period with those who did not.7
The same retrospective
analysis* further
demonstrated that
patients with PV and TEs
had higher rates of
outpatient healthcare
resource utilization
The same retrospective analysis* further
demonstrated that patients with PV and TEs had higher
rates of outpatient healthcare resource utilization
48.2% (104/216)
of patients with TEs
vs 26.3% (291/1106)
of patients without
TEs (P < 0.001)
48.2% (104/216) of patients
with TEs vs 26.3% (291/1106)
of patients without TEs (P < 0.001)
*Retrospective cross-sectional database analysis including 1322 adult patients with a PV diagnosis who were newly treated with hydroxyurea and continuously enrolled in medical and pharmacy benefit plans for ≥12 months pre- and post-index. Healthcare resource utilization and costs were analyzed in a subgroup analysis comparing patients who had TEs in the 12-month follow-up period with those who did not.7
*Retrospective cross-sectional database analysis including 1322 adult patients with a PV diagnosis who were newly treated with hydroxyurea and continuously enrolled in medical and pharmacy benefit plans for
≥12 months pre- and post-index. Healthcare resource utilization and costs were analyzed in a subgroup analysis comparing patients who had TEs in the 12-month follow-up period with those who did not.7
for patients with advanced PV who are at risk of a thrombotic event